115 Azithromycin affects the processing of tight junction proteins and ENaC in human airway epithelia in vitro  by Asgrimsson, V. et al.
$26 
~ Azithromycin affects the processing of tight junction proteins 
and ENaC in human airway epithelia in vitro 
V Asgrimsson 1 , T. Gudjonsson 2, G.H. Gudmundsson 3, S. Halldorsson 3,
O. Baldursson 4. llcelandic Cancer Society, 2Landspitali University Hospital 
Division of Hematology, 3University of Iceland Biology Institute, 4Landspitali 
University Hospital Division of Pulmonary Medicine, Iceland 
The macrolide antibiotic azithromycin mproves lung function and prognosis among 
patients with cystic fibrosis, independent ofbacterial eradication. Anti-inflammatory 
effects have been implicated but the link between abnormal CFTR and bronchial 
infections remains uncertain. We hypothesized that azithromycin might affect 
transepithelial electrolyte transport in human airway epithelia. 
To explore this possibility we treated human airway epithelia on filter supports 
with azithromycin and monitored transepithelial e ectrical resistance. We found 
that azithromycin i creased transepithelial electrical resistance of airway epithelia 
in a dose dependent manner from 1234±29 (control) to 2920±195 f2cm2±SEM 
(P< 0.05, n 24). Immunocytochemistry and western blot analysis showed that 
addition of azithromycin changed protein location in cell cultures and induced 
processing of tight juction proteins; claudin-1 and ~4, occludin and junctional 
adhesion molecule-A. These effects were reversible and neither produced by 
penicillin nor erythromycin. In addition, immunocytochemistry and western blot 
analysis indicated that azithromycin decreased the expression of ENaC in human 
airway epithelia. 
Conclusions: The data indicate that azithromycin may affect transepithelial elec- 
trolyte transport in human airway epithelia in vitro by affecting the processing of 
tight junction proteins and ENaC. The results are novel and may help explain the 
beneficial effects of azithromycin CE 
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~DNA release in Pseudomonas aeruginosa biofilms 
L. Yang, K.B. Barken, T. Tolker-Nielsen. Center for Biomedical Microbiology, 
Biocentrum, Technical University of Denmark, Building 301, DK-2800 Lyngby, 
Denmark 
Biofilm formation in Pseudomonas aeruginosa has been shown to play a significant 
role in chronic infection of cystic fibrosis patients. Extracellular DNA exists as 
one of the major matrix components in R aeruginosa biofilms. In a microtiter 
based assay employing the florescent DNA stain propidium iodide, it was shown 
that extracellular DNA was mainly released in the stationary growth phase. By 
comparing B aeruginosa PAO1 with different quorum sensing mutants we found 
that DNA release was under control of quorum sensing. The extracellular DNA was 
shown to originate from cell lysis by measuring the f3-galactosidase activity in the 
supernatant of a culture with a lacZ-containing R aeruginosa strain. Extracellular 
DNA has been shown to stabilize B aeruginosa biofilms. DNaseI treated flow 
cell biofilms were more sensitive to SDS treatment than untreated biofilms. We 
also tested DNA release from clinical isolates. The results showed that clinical 
isolates have large variation in the ability to release DNA and that this is related to 
their biofilm formation potential. These results show that DNA release in bacterial 
biofilms by cell lysis has an important physiological role for bacterial survival as a 
biofilm community. 
• Characterisation of bacterial community composition in 
Cystic Fibrosis lung infection using biofilm models 
T. Spasenovski 1 , G. Rogers 1, M. Carroll 2, K. Bruce 1 . 1Molecular Microbiology 
Lab, King ~' College London; 2Southampton University Hospitals', UK 
Many studies have considered that the bacterial community present in cystic fibrosis 
(CF) lung infections exists as a biofilm. Further, the ability of key CF pathogens such 
as Pseudomonas aeruginosa to resist antibiotic therapies may well largely be due to 
poor drug penetration of these biofilms. Current models for determining antibiotic 
susceptibility are based on non-biofilm-based modes of single species growth. 
However, this fails to represent the complex bacterial community now known to 
exist in the CF lung. In this study, we describe the successful generation of an in 
vitro biofilm model resembling the bacterial community sampled from CF lungs. 
These studies analysed the bacterial composition of biofilms generated directly from 
six adult CF sputum samples, during both early formation and maturation. The 
bacterial communities in both sputa and the biofilm models were characterised by
using terminal restriction fragment length polymorphism (T-RFLP) analysis of 16S 
rRNA gene PCR products amplified from directly extracted nucleic acids. Although 
some loss of diversity was observed uring biofilm maturation, the data generated 
showed that the bacterial community in sputa was well reproduced in the biofilm 
models. Typically, sputa contained 4.61±0.85 bacterial species, with species number 
decreasing to2.83 ±0.35 over 5 days. The generation ofbiofilm models directly from 
sputum represents a potentially powerful tool for the characterization f bacterial 
behavior in lung infections. The ability to screen responses to conventional therapies 
in vitro using biofilms will greatly increase the likelihood of novel treatments being 
identified. 
• Development of tolerance to the antimicrobial peptide Colistin 
in Pseudomonas aeruginosa biofilms 
S.J. Pamp, T. Tolker-Nielsen. Center of Medical Microbiology, BioCentrum-DTU, 
Denmarks Technical University, Denmark 
The biofilm mode of growth and development of subpopulations within these 
biofilms ofB aeruginosa is believed to be responsible for persistent lung infections 
in patients afflicted with cystic fibrosis. 
B aeruginosa wild type develops mushroom-shaped biofilms on a glass surface in 
presence of glucose as carbon source. The mushroom-cap is formed by cells which 
colonize the top of a microcolony via a process dependent on type IV pill. This 
cap-forming subpopulation is tolerant o treatment with the antimicrobial peptide 
Colistin, whereas the non-motile subpopulation, forming the stalk of the mushroom- 
like structure, is sensitive to Colistin, indicating that tolerance to antimicrobial 
treatment might be linked to a process dependent on type IV pill. To get more 
detailed information about he regulation of tolerance development, we investigated 
the role of the pilGHHchpABCDE chemosensory gene cluster regulating type 
IV pill in R aeruginosa, using flow cell technology and enhanced confocal aser 
scanning microscopy. 
Our data show, that all chemosensory mutants, develop mushroom-shaped biofilms, 
composed of two subpopulations. However, type IV pill-driven motility deficient 
strains develop an irregular cap structure, compared to the smooth cap formed by 
the wild type strain. Interestingly, the cap-forming subpopulation of all biofilms 
including the type IV pill-driven motility deficient strains, were tolerant to Colistin. 
Intriguingly, the stalk forming subpopulation formed by pilG, pilJ and pilK mutants 
remained tolerant, whereas wild type stalks are killed by Colistin. 
These data indicate that the chemosensory gene cluster might be involved in 
regulating tolerance development in subpopulations o fB  aeruginosa biofilms. 
